Table 44.
Country | GEN | STR | CIP | NAL | ERY | TET | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Prev. | 95% CI | Prev. | 95% CI | Prev. | 95% CI | Prev. | 95% CI | Prev. | 95% CI | Prev. | 95% CI | |
Austria | 0 | 0–1.8 | 3.7 | 0.6–5.1 | 38.2 | 31.4–45.3 | 32.6 | 26.2–39.7 | 0 | 0–1.8 | 27.9 | 22–35 |
Germany | 0 | 0–0.7 | 1.4 | 0.6–2.9 | 31.1 | 27–35.3 | 29.3 | 25.3–33.5 | 0 | 0–0.7 | 20.9 | 17.4–24.7 |
Hungary | 0 | 0–0.5 | 1.1 | 0.4–1.9 | 23 | 20.1–26.2 | 22.5 | 19.5–25.7 | 0 | 0–0.5 | 10.9 | 7.3–11.5 |
Italy | 0 | 0–0.5 | 0.8 | 0.3–1.7 | 13.6 | 11.3–16.2 | 10.2 | 8.2–12.5 | 0.5 | 0.1–1.3 | 11.5 | 9.3–13.9 |
Poland | 0 | 0–2.1 | 16.4 | 11.7–23.4 | 91.5 | 90.2–97.6 | 76.2 | 72.1–84.8 | 0.6 | 0–3.2 | 66 | 60.9–75.3 |
Portugal | 1.1 | 0.1–3.9 | 0 | 0–2 | 19.7 | 14.2–26.2 | 18.6 | 13.2–25 | 2.2 | 0.6–5.5 | 14.8 | 10–20.7 |
Romania | 0 | 0–11.6 | 0 | 0–11.6 | 40 | 22.7–59.4 | 33.3 | 17.3–52.8 | 0 | 0–11.6 | 30 | 14.7–49.4 |
Spain | 0 | 0–0.8 | 1 | 0.3–2.4 | 17.2 | 14–20.9 | 17.2 | 14–20.9 | 0 | 0–0.8 | 16.8 | 13.6–20.4 |
United Kingdom | 0 | 0–0.7 | 0.6 | 0.1–1.8 | 13.7 | 10.4–16.6 | 12.9 | 9.7–15.7 | 0.4 | 0–1.4 | 17.1 | 13.3–20 |
Total (9 MSs) | 0.06 | 0.01–0.2 | 1.8 | 1.4–2.3 | 24.1 | 22.7–25.6 | 21.7 | 20.4–23.1 | 0.3 | 0.2–0.6 | 18.2 | 17–19.5 |
ECOFFs: epidemiological cut‐off values; MSs: Member States; N: number of isolates tested; Prev.: percentage of slaughtered broilers (caecal samples) harbouring resistant isolates per category of susceptibility; 95% CI: 95% confidence interval of % Prev.; CIP: ciprofloxacin; ERY: erythromycin; GEN: gentamicin; NAL: nalidixic acid; STR: streptomycin; TET: tetracycline.